We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Tool for Automatic Colorectal Cancer Tissue Analysis Outperforms Prior Methods

By LabMedica International staff writers
Posted on 26 Oct 2023
Print article
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)

Colorectal Cancer (CRC) ranks as the third most prevalent and the second most lethal cancer. Catching it early and treating it promptly are extremely important. While machine vision technologies have seen remarkable improvements in automatically classifying types of cancer, they largely rely on deep neural networks with millions of parameters fine-tuned for diagnostic and prognostic tasks. Even though deep learning has shown extraordinary capabilities, healthcare professionals still have to inspect biopsied tissue samples to verify the diagnosis and assess the stage of the tumor. To advance this field further, scientists have now introduced an artificial intelligence (AI) solution specifically designed for automated analysis of colorectal cancer tissue that outperforms previous techniques.

The refined neural network developed by researchers from the University of Jyväskylä (Jyväskylä, Finland) has set new performance benchmarks in colorectal cancer tissue analysis. The AI-based system offers a more accurate and quicker way to categorize tissue samples of colorectal cancer from microscope slides. This advancement could significantly ease the work burden on histopathologists, thus enabling faster and more precise prognoses and diagnoses. Despite the promising results, it is important to be cautious while incorporating AI into medical practice.

As AI technologies move closer to becoming a standard part of clinical procedures, it becomes increasingly vital that they go through rigorous clinical validation. This is to ensure that the results they produce are consistently in line with established clinical norms. In a move encouraging collaborative development, the researchers are making this trained neural network publicly available. Their aim is to accelerate progress in the field by allowing scientists, researchers, and developers from around the world to further refine the tool and explore its various potential applications.

“By granting universal access, the aim is to fast-track breakthroughs in colorectal cancer research,” said Fabi Prezja, who was responsible for the design of the method.

Related Links:
University of Jyväskylä 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.